Your browser doesn't support javascript.
loading
Outcomes of non-angiosarcoma radiation-associated soft tissue sarcomas of the chest.
Garayua-Cruz, Leilani; Broida, Samuel E; Okuno, Scott H; Robinson, Steven I; Siontis, Brittany L; Welliver, Meng Xu; Wilke, Benjamin K; Goulding, Krista A; Rose, Peter S; Houdek, Matthew T.
Afiliación
  • Garayua-Cruz L; University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
  • Broida SE; Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Okuno SH; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Robinson SI; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Siontis BL; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Welliver MX; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Wilke BK; Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, Florida, USA.
  • Goulding KA; Department of Orthopedic Surgery, Mayo Clinic, Scottsdale, Arizona, USA.
  • Rose PS; Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Houdek MT; Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
J Surg Oncol ; 2024 Jun 12.
Article en En | MEDLINE | ID: mdl-38864186
ABSTRACT

BACKGROUND:

Radiation-associated soft tissue sarcomas (RA-STS) are rare complications of patients receiving radiation therapy (RT) and are generally associated with a poor prognosis. Most of the literature surrounding RA-STS of the chest is centered on angiosarcoma. Therefore, we aim to document the management and outcome of patients with non-angiosarcoma RA-STS of the chest.

METHODS:

We reviewed 17 patients (all female, median age 65 years) diagnosed with RA-STS. The most common primary malignancy was breast carcinoma (n = 15), with a median RT dose of 57.9 Gy. All patients underwent surgical resection; five patients (29%) received radiotherapy; and five patients (29%) received peri-operative chemotherapy.

RESULTS:

The 5-year local recurrence and metastatic-free survival were 61% and 60%, while the 5-year disease-specific survival was 53%. Local recurrence was associated with death due to disease (HR 9.06, p = 0.01). Complications occurred in nine of patients, most commonly due to a wound complication (n = 7). At the most recent follow-up, the median Musculoskeletal Tumor Society Score was 63%.

CONCLUSION:

RA-STS involving the chest wall are aggressive tumors with a high risk of local relapse and death due to disease. Local recurrence was associated with death due to disease; as such, we recommend aggressive surgical management with evaluation for adjuvant therapies.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Surg Oncol Año: 2024 Tipo del documento: Article País de afiliación: Puerto Rico

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Surg Oncol Año: 2024 Tipo del documento: Article País de afiliación: Puerto Rico